8-K 1 v028491_8k.htm Unassociated Document


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
 

 
DATE OF REPORT - November 7, 2005
(Date of Earliest Event Reported)
 
COLUMBIA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Commission File No. 1-10352

 
Delaware
  
59-2758596
(State of Incorporation)
  
(I.R.S. Employer
Identification No.)
     
354 Eisenhower Parkway
Livingston, New Jersey
  
 
07039
(Address of principal
executive offices)
  
Zip Code

 
Registrant’s telephone number, including area code: (973) 994-3999
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
Item 2.02 Results of Operations and Financial Condition

On November 7, 2005, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Third Quarter 2005 Results.” A copy of the press release issued by the Company is filed herewith as Exhibit 99.1.
 
The information contained in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this Current Report shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
 
Item 9.01 Financial Statements and Exhibits
 
(c)        Exhibits. 
 
 
99.1
Press Release dated November 7, 2005, entitled “Columbia Laboratories Reports Third Quarter 2005 Results.”
 
SIGNATURE
 

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 7, 2005
     
  COLUMBIA LABORATORIES, INC.
 
 		  
 		  
 
  By:   /S/ David L. Weinberg
 
David L. Weinberg
Vice President and Chief Financial Officer
   
 
 
Exhibit Index
 
Exhibit No.
Description
99.1
Press Release dated November 7, 2005, entitled “Columbia Laboratories Reports Third Quarter 2005 Results.”